As of March 31, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Gran Tierra, Immunovant, AIM, Cracker Barrel, JB Hunt: Insider Moves Unveiled!
- Immunovant’s Strategic Leadership and Portfolio Expansion Justify Buy Rating
- Immunovant downgraded to Neutral from Buy at UBS
- Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating